Abstract: Described herein are anti-inflammatory fractions and compounds, medicaments, methods and uses thereof. The fraction may be obtained from honey. The fraction shows a generalised anti-inflammatory response. Also described are method f producing the fraction as well as a method of testing the anti-inflammatory potential of a honey by completing the fractionation and a cell test.

Abstract: Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.

Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.

Abstract: Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

Abstract: A method of preventing, mitigating or treating Parkinson's Disease that includes administering an effective amount of a medicament comprised of Lactobacillus bulgaricus B-30892 and/or a supernatant resulting from culturing Lactobacillus bulgaricus B-30892 and/or bioactive materials resulting from culturing Lactobacillus bulgaricus B-30892 to a human to prevent, mitigate or treat Parkinson's Disease.

Abstract: This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.

Abstract: Provided is a food or drink composition for improving reflux esophagitis or skin diseases, containing fermented Eastern prickly pear.

Abstract: Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.

Abstract: The invention belongs to the field of traditional Chinese medicine (TCM), and in particular relates to an astragalus membranaceus seed raw oil and refined oil extracted from astragalus membranaceus seeds by using a supercritical extraction method, and to a use thereof in the preparation of health-care products. The astragalus membranaceus seed raw oil is obtained by supercritical CO2 fluid extraction on the astragalus membranaceus seeds; and the astragalus membranaceus seed refined oil is obtained by physically refining the astragalus membranaceus seed raw oil. The astragalus membranaceus seed raw oil and refined oil have the effects of preventing thrombosis and dilating blood vessels, can also prevent diseases such as atherosclerosis, hypertension, hyperglycemia and high cholesterol, and can be used as a long-term dietary health-care oil product for cardiovascular patients.

Abstract: A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

Abstract: A composition with anoxia-tolerant and anti-fatigue functions, which is prepared by the following active ingredients: Arillus Longan, Fructus Jujubae, Radix Rehmanniae Preparata, Fructus Lycii, Semen Juglandis, Fructus Schisandrae Chinensis, Cortex Cinnamomi, and Ccornu Cervi Pantotrichum. The invention further provides a use of aforesaid composition in the preparation of the health food with anoxia-tolerant and anti-fatigue functions. The health food of the present invention is prepared with natural Chinese herbal medicine as the major raw materials, can be administered for a long time, the result of functional experiment prove that, the health food of the present invention has anoxia-tolerant and anti-fatigue functions, the effect is significant.

Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.

Abstract: A capsule with a shell and a fill phase. The fill phase contains less than about 5% beeswax by weight of the capsule and a supercritical extract of an herb. The capsule can be both vegetarian and meet the non-GMO Project Standard.

Abstract: Disclosed herein are compositions and methods for modulating DNA methylation of one or more gene promoters, treating a subject diagnosed with or suspected of having a disease or disorder characterized by DNA hypermethylation, decreasing c-myc expression, increasing desmoplakin expression, and inhibiting metastases. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.

Abstract: The present invention provides, among other things, methods of treating amyotrophic lateral sclerosis including administering to a subject suffering from amyotrophic lateral sclerosis an angiotensin (1-7) peptide. In some embodiments, an angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of amyotrophic lateral sclerosis is reduced in intensity, severity, duration, or frequency or has delayed onset.

Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of at least one iron chelator, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to at least one iron chelator and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2?6?-Dmt-Lys-Phe-NH2.

Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).

Abstract: An application of a recombinant immunoregulatory protein of ganoderma lucidum (rLZ-8) expressed by Pichia pastoris in a preparation of a drug for treating focal cerebral ischemia is provided. The rLZ-8 is able to treat a neurological function injury, decrease a neurological severity score caused by a cerebral injury and decrease an ED-1 positive cell number, so as to decrease an inflammatory response and inhibit apoptosis.

Abstract: According to aspects illustrated herein, there is provided an agent that transiently disrupts claudin-1 within tight junctions. The agent includes a peptide having at least 40% polar, uncharged amino acid residues and a self-assembled ?-sheet secondary structure. According to aspects illustrated herein, there is also provided a transepithelial drug and vaccine formulations, as well as isolated peptides, pharmaceutical compositions, and transdermal delivery devices. Also described herein are methods of disrupting epithelial barrier and methods of administering the transepithelial formulations described herein.

Abstract: A method of inhibiting protein kinases by administering polypeptides derived from alpha-neurotoxin, and inhibiting protein kinases. Diseases treated thereby include cancer, influenza, Tourette's syndrome, pain, and neurological deficits.

Abstract: The invention relates to the identification of a novel epitope on non-function P2X7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the three subunit receptor. Antibodies which bind to the epitope and peptides for generating the antibodies are described. The antibodies and peptides are useful in the diagnosis and treatment of cancer.

Abstract: Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a DNA-binding polypeptide, fused to a mitochondrial targeting sequence (MTS) and a nuclear export signal (NES), and the encoded proteins. The construct successfully delivers DNA binding proteins to the mitochondrion. A chimeric methylase based on the above construct is successfully delivered to mitochondria, resulting in modification of mtDNA.

Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling.

Abstract: The present invention relates to the diagnostic and therapeutic uses of Arpin, a protein from the Uncharacterized Protein Family UPF0552, which is a new inhibitor of the Arp2/3 that inhibits cell migration and is associated with the prognosis of cancer.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with anti-apoptotic agent or pro-apoptotic agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Abstract: The present invention refers to lipid nanoparticles comprising a growth factor and/or an antimicrobial peptide and to the method for their preparation. Moreover, it refers to pharmaceutical compositions comprising such lipid nanoparticles, and a pharmaceutical acceptable carrier. Finally, it also refers to said pharmaceutical composition for its use as medicament and for its use in promoting wound healing, particularly by topical administration.

Abstract: A pharmaceutical composition and method for treating or attenuating a mood or stress-related disorder in a subject having normal or low inflammatory state is provided. In some embodiments, the pharmaceutical composition and method of the invention comprise activating or stimulating microglia for treatment of mood or stress-related disorder.

Abstract: This disclosures relates to methods of preventing or reducing antigenic drift, viral reassortment and symptoms of wild-type and mutant influenza viruses in a host animal by determining if a host animal has been exposed to or infected by an avian influenza virus, and administering to the exposed host animal ?-interferon.

Abstract: The present disclosure provides biocompatible scaffold that promotes M1 or M2 macrophage phenotypes so as to increase vascularization or healing. Also provided are methods of treating a subject in need with the scaffolds described here.

Abstract: The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.

Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.

Abstract: The present disclosure is directed to transdermal and moisturizing compositions.

Abstract: The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.

Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Abstract: The present invention relates generally to compositions and methods of using compositions comprised of undenatured cartilage in the form of an isolated native Type II collagen that may be combined in a synergistic blend with one or more edible metals with acceptable chemical counter-ions or other health promoting ingredients to be orally consumed as a method for preventing and improving symptoms of musculoskeletal distress degeneration, including symptoms selected from temporary loss of range of motion, temporary inflammation, temporary muscle soreness, and combinations thereof. The synergistic compositions of the present invention also protect, promote and improve recovery from and prevention of cartilage and ligament wear, thinning and damage to bone, and repetitive motion injuries and stress resulting from intense periods of activity or workout routines that contribute to such musculoskeletal distress degeneration symptoms.

Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.

Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.

Abstract: A treatment for pruritus is described that is based upon amylase. The amylases (?-, ?-, ?-amylase) are noted for the cleavage of the ?-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments. It has now been found that ?-amylase is effective in the reduction of pruritus (itching) of affected tissue.

Abstract: The invention provides a formulation for treating stress and lessening fatigue. The formulation can be combined with water or another suitable liquid to provide a beverage for ease of administration. The formulation can include one or more of an energy compound, a vasodilator, a vasodilator adjuvant, and an antioxidant enhancer. In a typical formulation the energy compound is D-ribose or guanosine. The formulation can improve energy and alertness, and reduce the effects of stress and fatigue.

Abstract: This invention relates generally to treating synucleinopathies in subjects that are not clinically diagnosed with a lysosomal storage disease, as well as associated methods of making medicaments and screening methods.

Abstract: Provided are compositions and methods for prophylaxis and/or therapy of ErbB2-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB2-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB2-positive cancer.

Abstract: The invention features compositions comprising HDAC2 and methods for protecting the vascular endothelium from injury.

Abstract: The invention features alginate and alginate lyase compositions and methods that are useful for the treatment of various conditions and diseases. The invention also provides kits and instructions for use.

Abstract: A process for the endogenic catabolism of homocysteine and the control of homocysteine levels for treating disease and the degenerative diseases of aging is provided along with pharmaceutical compositions having thioretinamide, retinol or combinations thereof in combination with an enzyme or a pro-enzyme. The process includes the catabolism of homocysteine thiolactone in cells and tissues by catalyzing the reaction of homocysteine thiolactone with an enzyme-bound retinoic acid to increase the bioavailability of thioretinamide in diseased and aged cells and tissue.

Abstract: The present invention includes methods for reducing tissue damage in patients undergoing radiation treatment or with idiopathic pulmonary fibrosis or scleroderma by inhibiting PAI-1 activity in the tissue with a truncated PAI-1 agent, rPAI-123.

Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Abstract: Antibodies binding to sites on the alpha-subunit of the (Na++K+)-ATPase increase cardiac contraction of both ventricular myocytes and mouse heart. In particular, antibodies binding to the RSATEEEPPNDD (SEQ ID NO: 1) or DVEDSYGQQTYEQR (SEQ ID NO: 2) peptides (or isoforms/derivatives thereof) of the alpha-subunit of the (Na++K+)-ATPase, have been found to be highly inotropic. Both the antibodies and the peptides are important for the treatment of human heart failure and other contractile disorders.

Abstract: A pharmaceutical composition comprising at least two peptides of from 20 to 60 amino acids in length, selected from peptides comprising a sequence of at least 20 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 40 and 48 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: 1 to 40 and 48, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope.

Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.